rare cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) is back on traders’ radars today after unveiling a rare immune‑complete response in a patient with metastatic triple‑negative breast cancer (TNBC) – even as the micro‑cap oncology company discloses a fresh Nasdaq delisting warning and files a new prospectus supplement with the U.S. SEC. Nasdaq+2Investing.com Australia+2 Key Takeaways for 19 November 2025 Rare Immune‑Complete Response in Metastatic Triple‑Negative Breast Cancer The core of today’s excitement is an update on a single, heavily pre‑treated patient with stage IV triple‑negative breast cancer, one of the most aggressive and difficult‑to‑treat breast‑cancer subtypes. Kazia had previously reported an 86%